Panacea Biotec shares jumped 9.3 per cent on BSE, logging an intra-day high at ₹418.35 per share. The buying on the counter came after the company said enrollment is complete for the Phase III ...
The Print on MSN
India’s first dengue vaccine has been in the making for 17 yrs. DengiAll has the world excited
At the Panacea Biotec office, conversations around DengiAll are cloaked with an air of eagerness. With the human trials ending with over 10,000 participants, the company is waiting for approval.
Panacea Bio share price has gained 7.27% in the past five sessions and nearly 21% in a month. However, the scrip has declined by over 11% a year.
The company said a total of 10,335 participants have been enrolled in the late stage trial. Each participant will be monitored for a period of two years after receiving either the vaccine or a placebo ...
DengiAll emerges as a promising single-dose solution offering balanced protection against all four dengue types.
Details Of Shares Dematerialized During December 2025 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations, 2018 - Rediff MoneyWiz, the personal finance service from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback